Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611130 · ClinicalTrials.gov registry record · Phase 2
Vigabatrin for Treatment of Cocaine Dependence
A Phase 2 study of Cocaine Dependence, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
- 11
- Study locations
NCT00611130 is a Phase 2 study of Cocaine Dependence that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 186 participants, below the 294-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (37% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT00611130, a Phase 2 study of Cocaine Dependence, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
- 11
- Study locations
Study Summary
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.
Conditions Studied
Interventions
- DRUG placebo
- DRUG vigabatrin
Study Locations (11)
California
- St. Luke's Hospital Addiction Pharmacology Research Laboratory - San Francisco
- Friends Research Institute - Torrance
Florida
- Operation PAR - Largo
- Segal Institute for Clinical Research - North Miami
Ohio
- Cincinnati Addiction Research Center (CinARC) - Cincinnati
- Dayton Veterans Affairs Medical Center - Dayton
Arkansas
- Addiction Treatment Clinic - Little Rock
Maryland
- Johns Hopkins Bayview Medical Center Center for Chemical Dependence - Baltimore
Massachusetts
- Boston University School of Medicine - Boston
New York
- New York University Mental Health and Addictive Disorders Research Program - New York
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611130
The ClinicalTrials.gov registry entry for NCT00611130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 294-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (37% lower). The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine Dependence appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00611130 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT00611130 about?
NCT00611130 is a clinical study titled "Vigabatrin for Treatment of Cocaine Dependence". The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.
What is the current status of trial NCT00611130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2008-01. Estimated completion is 2012-10.
What conditions does trial NCT00611130 study?
This clinical trial studies the following conditions: Cocaine Dependence.
What interventions are being tested in trial NCT00611130?
The interventions under investigation include: placebo (DRUG), vigabatrin (DRUG).
Who is sponsoring clinical trial NCT00611130?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00611130 being conducted?
This trial has 11 study locations across Arkansas, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Glutamatergic Modulation of Cocaine-related Deficits
COMPLETED · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
Citalopram for Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.